Shots:

• The P-III Measure Up 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adults and adolescents aged 12-18yrs. or older with mod. to sev. AD who are candidates for systemic treatment. Placebo patients were switched to either upadacitinib (15/30mg) @16wks.
• The study met its co-1EPs @16wks. i.e. improvement in EASI 75 (60%/73% vs 13%)- patient achieving vIGA-AD 0/1 (39%/52% vs 5%); reduction in itch (42%/60% vs 9%); Improvement in Worst Pruritus NRS≥4 (42%/60% vs 9%) respectively
• Rinvoq (qd) is a selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases and has received the US FDA’s approval for patients with mod. to sev. active RA having inadequate response or intolerance to MTX. The therapy is under P-III study for AD- RA- PsA- axSpA- CD- UC and giant cell arteritis

  Ref: PRNewswire | Image: abbvie